DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...

It has had strong momentum since November, but there is still plenty of upside left.

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BillionToOne, Inc. Class A ( BLLN – Research Report) and Dexcom ( DXCM – Research Report ).

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full ...